Cap Insulin Prices Act
Latest Action
Committee on Banking, Housing, and Urban Affairs. Hearings held. Hearings printed: S.Hrg. 118-558.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The Cap Insulin Prices Act is a Senate bill from the 118th Congress aimed at limiting the cost of insulin for consumers. Although the full text and official summary are not available, the bill's title and policy area indicate its focus on controlling insulin prices to improve affordability. The latest recorded action was a committee hearing held by the Senate Committee on Banking, Housing, and Urban Affairs on June 12, 2024. The bill status is marked as failed or expired, indicating it did not advance into law during the 118th Congress.
This bill sought to cap insulin prices to make the medication more affordable but did not pass during the 118th Congress.
- The bill is titled 'Cap Insulin Prices Act' and focuses on health policy.
- It was introduced in the Senate during the 118th Congress.
- The latest legislative action was a committee hearing in June 2024.
- The bill ultimately failed or expired without becoming law.
- No official summary or full text is publicly available for detailed analysis.
['People who use insulin for diabetes management', 'Healthcare providers prescribing insulin', 'Potentially health insurance programs and government health agencies involved in diabetes care']
['Lack of publicly available full bill text limits detailed understanding of implementation mechanisms.', 'Potential challenges in enforcement and oversight of price caps if included.', 'Possible tradeoffs related to pharmaceutical industry pricing and supply considerations.', 'Unclear funding or authority provisions due to missing bill text.']
The bill was considered during the 118th Congress and was referred to the Senate Committee on Banking, Housing, and Urban Affairs, which held hearings in mid-2024. Despite this, the bill did not advance to passage and is recorded as failed or expired. The legislative context reflects ongoing congressional interest in addressing drug pricing, particularly for essential medications like insulin.
Hidden impact flags detected: 2
GovScope reviewed 2 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['Potential reduction in out-of-pocket costs for insulin users if price caps were implemented.', "Possible impact on pharmaceutical manufacturers' pricing strategies and revenue.", 'Changes in insurance coverage policies related to insulin.', 'Increased congressional and public focus on drug pricing reforms.']
Transparency is limited due to the absence of the full bill text and official summary, which constrains detailed policy analysis and public understanding. The bill's failure to advance suggests limited legislative momentum during the 118th Congress. Oversight considerations include how price caps would be enforced and funded, which cannot be assessed without the full text.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.